bluebird bio Inc (NASDAQ:BLUE) has received a consensus recommendation of “Buy” from the nineteen analysts that are presently covering the stock. One equities research analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and eleven have assigned a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $87.80.
Several analysts have recently weighed in on BLUE shares. Roth Capital set a $87.00 price target on bluebird bio and gave the stock a “buy” rating in a report on Thursday, December 1st. Jefferies Group LLC set a $88.00 price target on bluebird bio and gave the stock a “buy” rating in a report on Thursday, December 1st. Cantor Fitzgerald restated a “sell” rating on shares of bluebird bio in a report on Saturday, December 10th. Zacks Investment Research cut bluebird bio from a “buy” rating to a “hold” rating in a report on Monday, January 30th. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $95.00 price target on shares of bluebird bio in a report on Wednesday, November 30th.
In other bluebird bio news, Director John Maraganore sold 13,839 shares of the stock in a transaction that occurred on Friday, March 3rd. The stock was sold at an average price of $85.02, for a total transaction of $1,176,591.78. Following the transaction, the director now directly owns 5,765 shares in the company, valued at approximately $490,140.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Jason Cole sold 549 shares of the stock in a transaction that occurred on Thursday, January 5th. The stock was sold at an average price of $67.10, for a total value of $36,837.90. Following the transaction, the insider now owns 9,389 shares in the company, valued at $630,001.90. The disclosure for this sale can be found here. Insiders have sold a total of 34,826 shares of company stock worth $2,733,225 over the last 90 days. Company insiders own 3.50% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. FMR LLC boosted its position in bluebird bio by 9.2% in the fourth quarter. FMR LLC now owns 6,088,971 shares of the company’s stock worth $375,689,000 after buying an additional 513,477 shares during the last quarter. Baillie Gifford & Co. raised its position in shares of bluebird bio by 3.3% in the fourth quarter. Baillie Gifford & Co. now owns 5,164,467 shares of the company’s stock worth $318,647,000 after buying an additional 165,634 shares during the last quarter. BlackRock Fund Advisors raised its position in shares of bluebird bio by 6.4% in the third quarter. BlackRock Fund Advisors now owns 1,475,395 shares of the company’s stock worth $100,002,000 after buying an additional 89,166 shares during the last quarter. BlackRock Institutional Trust Company N.A. raised its position in shares of bluebird bio by 3.6% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 935,722 shares of the company’s stock worth $63,423,000 after buying an additional 32,756 shares during the last quarter. Finally, Victory Capital Management Inc. raised its position in shares of bluebird bio by 227,306.3% in the third quarter. Victory Capital Management Inc. now owns 654,930 shares of the company’s stock worth $44,391,000 after buying an additional 654,642 shares during the last quarter.
Shares of bluebird bio (NASDAQ:BLUE) traded down 2.22% during mid-day trading on Monday, hitting $90.35. 376,502 shares of the company were exchanged. bluebird bio has a 12-month low of $35.37 and a 12-month high of $100.40. The firm has a 50 day moving average of $81.50 and a 200 day moving average of $67.35. The company’s market capitalization is $3.69 billion.
bluebird bio (NASDAQ:BLUE) last released its quarterly earnings results on Wednesday, February 22nd. The company reported ($1.88) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.86) by $0.02. The firm had revenue of $1.55 million for the quarter, compared to the consensus estimate of $1.76 million. bluebird bio had a negative return on equity of 30.79% and a negative net margin of 3,941.72%. The business’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter last year, the firm posted ($1.29) earnings per share. Equities research analysts forecast that bluebird bio will post ($7.31) earnings per share for the current year.
Your IP Address:
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc and related companies with MarketBeat.com's FREE daily email newsletter.